RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
2,703actual
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-31 | actual | When the study began enrolling |
| Primary completion | 2025-03-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-14 | actual | The whole study's end, after follow-up |
| First posted | 2025-01-24 | actual | When this record first appeared on the registry |
| Results posted | 2026-05-15 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-05-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lymphoma
Interventions
- Drug: Rituximab Pfizer
- Drug: Rituxan
Primary outcome
what the primary-completion date above is the date OFIncidence of Infections Which Requires Procedures, Medication or Hospitalization
measured From index date up to 180 days after last dose, with a maximum of 5 years (the end of the study period)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-11-14 · 5.6 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-01-28 · 626 KB · SAP_001.pdf
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed